Teva Announces Approval and Shipment of Generic Coreg Tablets

Teva Pharmaceutical announced that the FDA has granted final approval for the company's abbreviated new drug application to market its generic version of GlaxoSmithKline’s cardiovascular agent Coreg in 3.125-, 6.25-, 12.5- and 25-mg doses.

Teva said shipment of this product will begin immediately.

The brand product had annual sales of approximately $1.7 billion in the U.S. for the twelve months ending June 30, based on IMS sales data.